car-t therapy, cartitude-1 ciltacabtagene autoleucel in rrmm patients | yi lin, md, phd | asco 2023
Published 1 year ago • 241 plays • Length 3:27
Download video MP4
Download video MP3
Similar videos
-
2:01
managing car-t cell therapy in the real world | yi lin, md, phd | ims 2023
-
4:21
phase 1 study phe885 bcma-directed car-t cell therapy for rrmm | adam sperling, md, phd | asco 2023
-
1:38
cartitude-1 final results: pfs of cilta-cel in patients with heavily pre-treated r/r myeloma
-
2:25
cartitude-1 final results: cilta-cel in heavily pretreated patients with r/r myeloma
-
2:57
efficacy outcomes of patients with myeloma who achieved sustained mrd negativity in cartitude-1
-
8:29
car-t therapy options for multiple myeloma
-
1:07
updated results from cartitude-1
-
2:24
yi lin, md, phd, on how anti-bcma car-t cell therapy fits into the treatment of rrmm
-
2:08
value of mrd status one month after car-t therapy in patients with multiple myeloma
-
4:49
panel highlights key myeloma takeaways from asco 2023
-
5:03
panelists discuss access to car-t for patients with myeloma
-
2:05
meta-analysis of cilta-cel in patients with r/r multiple myeloma
-
0:57
what is car-t cell therapy?
-
4:36
outcomes from the cartitude-1 study assessing car t-cell therapy for multiple myeloma
-
1:53
yi lin, md, phd, offers opinion on anti-bcma car-t cell therapy
-
6:10
panel discusses novel bcma-targeted car-t therapies in the myeloma pipeline
-
1:00
side effects of car t cell therapy
-
3:06
prognostic value of early bone marrow and pet mrd assessment in car-t therapy for multiple myeloma
Clip.africa.com - Privacy-policy